Holen Sie sich die Stockscreener-App
0.00065
0.00%
0.00015
Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten
Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Head-To-Head Review: Aerovate Therapeutics (NASDAQ:AVTE) vs. Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
SYRS (Syros Pharmaceuticals) Price-to-Tangible-Book : (As of Oct. 22, 2025) - GuruFocus
CapEx per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Net current asset value per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $3.33 - Defense World
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - The Manila Times
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - Investing.com Canada
Odyssey hires Jason Haas as CFO - BioCentury
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - Nasdaq
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
Syros stock dives 92% on failed Phase 3 study, possible loan default (NASDAQ:SYRS) - Seeking Alpha
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - The Malaysian Reserve
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - simplywall.st
Syros Pharmaceuticals Executives Increase Holdings - TradingView — Track All Markets
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gew - GuruFocus
Syros Pharmaceuticals, Inc. (SYRS) Investigation: - GlobeNewswire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings - Business Wire
How to contact the Daily Bulletin - FinancialContent
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
Syros Pharma tanks as it updates on SELECT-AML-1 study | Biotechnology | The Pharmaletter - The Pharma Letter
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today? - TradingView — Track All Markets
Syros ending enrollment in phase 2 leukemia study - Seeking Alpha
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update - Stock Titan
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why - Nasdaq
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout - Seeking Alpha
TD Cowen maintains Buy on Syros Pharmaceuticals stock amid trial optimism - Investing.com Canada
Irving’s McKesson Corp. Adds Healthcare Veteran to Board - Dallas Innovates
McKesson Elects Deborah Dunsire as Director - citybiz
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
Syros Pharmaceuticals (SYRS) Stock Forecast and Price Target 2025 - MarketBeat
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 - Business Wire
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals - Yahoo Finance
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression - Business Wire
Syros Pharmaceuticals CMO sells over $50k in company stock By Investing.com - Investing.com Canada
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Earnings call: Syros Pharmaceuticals strong Q4 and full year financials - Investing.com
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Thinking about buying stock in Biofrontera, Snowflake, Syros Pharmaceuticals, Agenus, or Kopin? - MarketScreener
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why - Nasdaq
Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice - Yahoo Finance
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene - Business Wire
Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals - Yahoo Finance
Here’s What Insiders Are Buying to Wrap Up the Year - 24/7 Wall St.
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants - Business Wire
0.55%
0.29%
Kapitalisierung:
|
Volumen (24h):